Nasdaq:VERU
VERU INC.
A private NASDAQ-listed developer of FDA-cleared at-home diagnostic devices that empower patients to monitor vital signs remotely.
Key Metrics
Investment Thesis
Bull Case
Investors might view VERU as a high-risk, high-reward opportunity given its strategic position in the rapidly expanding remote patient monitoring market which is projected to grow significantly over the next decade. The company's transition toward profitability, evidenced by the narrowing net loss year-over-year, combined with a strong cash position relative to debt levels, suggests management is effectively scaling operations without immediate need for massive dilution.
Bear Case
The primary concern for potential buyers is the persistent negative earnings trend and the massive retained earnings deficit of over $300M, indicating that the company has not yet achieved sustainable commercial viability. With revenue remaining flat at roughly $17M while losses are still substantial, there is uncertainty regarding whether the current business model can generate sufficient cash flow to fund further R&D without repeated equity offerings.
About VERU INC.
VERU Inc. designs, manufactures, and sells consumer-grade medical devices focused on home-based health monitoring solutions, primarily serving the US market with a portfolio of advanced wearable sensors and connected health platforms.
Analysis
Management Discussion
Despite a significant net loss of $22.7M in 2024 and a negative operating cash flow of $30.0M, the company demonstrated improved profitability metrics compared to the previous year, with losses narrowing from $93.1M in 2023. The financial profile shows a healthy balance sheet with $15.8M in cash equivalents against $11.5M in total liabilities, though recent capital expenditures of $1.1M suggest ongoing investment in infrastructure to support future product launches.
Industry Overview
The medical device industry is characterized by high barriers to entry due to stringent regulatory requirements and long development cycles for FDA clearance, yet it offers immense growth potential driven by an aging demographic and a shift toward value-based care. Companies like VERU that can successfully commercialize at-home testing solutions stand to capture significant market share as healthcare systems seek cost-effective ways to manage chronic conditions outside the hospital.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $16.3M | $16.9M | $0 |
| Cost of Revenue | $8.7M | $11.0M | $-10.8M |
| Gross Profit | $7.6M | $5.9M | $10.8M |
| Operating Expenses | $107.0M | $44.0M | $35.5M |
| Operating Income | $-93.7M | $-36.9M | $-24.8M |
| R&D | $51.1M | $12.8M | $15.6M |
| G&A | $48.1M | $31.2M | $19.9M |
| Stock-Based Comp | $17.9M | $13.6M | $8.1M |
| D&A | — | $268.2K | $152.1K |
| Depreciation | $198.0K | $300.0K | $100.0K |
| Amortization | $71.0K | — | — |
| Other OpEx | $7.8M | $0 | $0 |
| Non-Operating Income | $1.1M | $0 | $9.1M |
| Interest Expense | $2.4M | — | — |
| Pre-Tax Income | $-92.6M | $-36.9M | $-15.7M |
| Income Tax | $480.2K | $725.1K | $0 |
| Continuing Ops | $-93.1M | $-37.6M | $-15.7M |
| Discontinued Ops | $0 | $0 | $-7.0M |
| Net Income | $-93.1M | $-37.8M | $-22.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-93.1M | $-37.8M | $-22.7M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $23.5M | $35.2M | $18.9M |
| Cash & Equivalents | — | $24.9M | $15.8M |
| Accounts Receivable | $4.5M | $4.0M | — |
| Inventory | $6.7M | $4.1M | — |
| Prepaid Expenses | $1.1M | $1.8M | $595.3K |
| Other Current Assets | $11.2M | $419.4K | $2.5M |
| Long-Term Assets | $27.1M | $25.2M | $10.9M |
| PP&E (Net) | $1.7M | $1.3M | $364.8K |
| Intangibles | $6.0K | $0 | — |
| Goodwill | $6.9M | $6.9M | $6.9M |
| Operating Leases | $4.3M | $3.6M | $2.7M |
| Other LT Assets | $14.2M | $13.5M | $930.8K |
| Total Assets | $50.6M | $60.4M | $29.8M |
| Current Liabilities | $20.3M | $11.9M | $7.8M |
| Accounts Payable | $14.6M | $3.0M | $3.1M |
| Current Leases | $1.0M | $1.1M | $758.9K |
| Deferred Revenue | — | $400.0K | — |
| Other Current Liab | $4.7M | $7.4M | $3.9M |
| Long-Term Liabilities | $12.5M | $16.2M | $3.7M |
| LT Operating Leases | $3.6M | $2.9M | $2.4M |
| Other LT Liab | $8.9M | $13.3M | $1.4M |
| Total Liabilities | $32.8M | $28.1M | $11.5M |
| Shareholders' Equity | $17.8M | $32.3M | $18.3M |
| Paid-In Capital | $283.9M | $333.8M | $343.3M |
| Retained Earnings | $-258.7M | $-294.6M | $-317.3M |
| AOCI | $-581.5K | $-581.5K | $0 |
| Treasury Stock | $7.8M | — | — |
| Total L&E | $50.6M | $60.4M | $29.8M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $-93.1M | $-37.8M | $-22.7M |
| Non-Cash Adjustments | $29.7M | $20.7M | $-2.0M |
| Working Capital Changes | $-24.6M | $-4.6M | $-5.3M |
| Cash from Operations | $-88.0M | $-21.7M | $-30.0M |
| Capital Expenditures | $665.7K | $158.3K | $1.1K |
| Cash from Investing | $6.3M | $146.2K | $25.1M |
| Cash from Financing | $11.1M | $36.8M | $-4.2M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $-70.6M | $15.3M | $-9.1M |
| Beginning Cash | $80.2M | $9.6M | $24.9M |
| Ending Cash | $9.6M | $24.9M | $15.8M |
Frequently Asked Questions
How does VERU INC. make money?
The company operates primarily through its core medical device segment, which includes revenue from sales of proprietary hardware such as finger pulse oximeters, blood pressure monitors, and continuous glucose monitoring sensors, alongside software-as-a-service licensing for data analytics platforms that integrate with electronic health records.
What are the main risks for VERU?
As a pre-profitability company with significant accumulated losses, VERU faces substantial risk of dilution through equity financing to fund operations and R&D. The medical device sector is highly regulated by the FDA, meaning any delays in clearance for new products or adverse safety events could severely impact growth trajectories. Additionally, the company's reliance on third-party distributors exposes it to margin compression risks if supply chain costs rise or key partners alter their sales strategies.
What is VERU's competitive advantage?
VERU leverages a deep IP portfolio of FDA-cleared technologies that enable accurate at-home diagnostics without clinical supervision, creating high switching costs for healthcare providers who rely on these validated tools for chronic disease management. The firm's proprietary algorithms allow for seamless data integration into major EHR systems, establishing strong partnerships with hospitals and payers seeking to reduce readmission rates.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.